Literature DB >> 2551943

Cisplatin combination chemotherapy in squamous cell carcinoma and adenoid cystic carcinoma of the skin.

S Ikegawa, T Saida, H Obayashi, A Sasaki, H Esumi, S Ikeda, Y Kiyohara, K Hayasaka, K Ishihara.   

Abstract

Seven patients with skin cancers, six with squamous cell carcinoma (SCC) and one with adenoid cystic carcinoma, were treated with cisplatin in combination with vindesine or adriamycin. Partial response was observed in three patients with squamous cell carcinomas: two cases with metastatic lung lesions and one with a primary skin lesion and lymph node metastasis. Two of the responding SCC had been resistant to previous chemotherapy, including peplomycin and mitomycin C. Multiple metastatic lesions of adenoid cystic carcinoma of the skin completely regressed after two courses of the combination chemotherapy with cisplatin and adriamycin. This report showed that cisplatin combination chemotherapy may be useful for the treatment of cutaneous squamous cell carcinoma, which is resistant to peplomycin, and adenoid cystic carcinoma of the skin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2551943     DOI: 10.1111/j.1346-8138.1989.tb01254.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  13 in total

1.  A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck.

Authors:  Carol M Lewis; Bonnie S Glisson; Lei Feng; Fiona Wan; Ximing Tang; Ignacio I Wistuba; Adel K El-Naggar; David I Rosenthal; Mark S Chambers; Robert A Lustig; Randal S Weber
Journal:  Clin Cancer Res       Date:  2012-01-18       Impact factor: 12.531

2.  Primary cutaneous adenoid cystic carcinoma in the United States: incidence, survival, and associated cancers, 1976 to 2005.

Authors:  Graça M Dores; Mark M Huycke; Susan S Devesa; Carlos A Garcia
Journal:  J Am Acad Dermatol       Date:  2010-05-05       Impact factor: 11.527

3.  Recurrent and metastatic trichilemmal carcinoma of the skin over the thigh: a case report.

Authors:  Hyon Seung Yi; Sun Jin Sym; Jinny Park; Eun Kyung Cho; Seung-Yeon Ha; Dong Bok Shin; Jae Hoon Lee
Journal:  Cancer Res Treat       Date:  2010-09-30       Impact factor: 4.679

4.  Primary cutaneous adenoid cystic carcinoma with MYB aberrations: report of three cases and comprehensive review of the literature.

Authors:  Carlos N Prieto-Granada; Lei Zhang; Cristina R Antonescu; Jean M Henneberry; Jane L Messina
Journal:  J Cutan Pathol       Date:  2016-12-02       Impact factor: 1.587

5.  Cutaneous adenoid cystic carcinoma with perineural invasion treated by mohs micrographic surgery-a case report with literature review.

Authors:  Yaohui G Xu; Molly Hinshaw; B Jack Longley; Humza Ilyas; Stephen N Snow
Journal:  J Oncol       Date:  2010-04-07       Impact factor: 4.375

6.  Accumulated cytotoxicity of CDK inhibitor dinaciclib with first-line chemotherapy drugs in salivary adenoid cystic carcinoma cells.

Authors:  Laijun Xu; Lingzhi Li; Jun Zhang; Wenping Cai; Shouliang Zhao; Shangfeng Liu
Journal:  Odontology       Date:  2019-09-16       Impact factor: 2.634

7.  Survival study and clinicopathological evaluation of trichilemmal carcinoma.

Authors:  Shi-Min Zhuang; Ge-Hua Zhang; Wen-Kuan Chen; Shu-Wei Chen; Li-Ping Wang; Huan Li; Ming Song
Journal:  Mol Clin Oncol       Date:  2013-01-30

8.  Primary Adenoid Cystic Carcinoma of the Skin with Multiple Local Recurrences.

Authors:  Ivan Dimitrov Tonev; Yana Stoeva Pirgova; Nikolay Vladimirov Conev
Journal:  Case Rep Oncol       Date:  2015-06-03

Review 9.  Novel Therapeutic Targets in Cutaneous Squamous Cell Carcinoma.

Authors:  Teruki Yanagi; Shinya Kitamura; Hiroo Hata
Journal:  Front Oncol       Date:  2018-03-23       Impact factor: 6.244

Review 10.  Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Apocrine and Eccrine Differentiation.

Authors:  Iga Płachta; Marcin Kleibert; Anna M Czarnecka; Mateusz Spałek; Anna Szumera-Ciećkiewicz; Piotr Rutkowski
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.